PR Newswire PharmaOriginal article
DifGen Pharmaceuticals LLC Announces U.S. FDA Approval of Epinephrine Injection USP, 1 mg/mL, Single-Dose Vials
RegulatoryapprovedEpinephrine Injection USP, 1 mg/mL, Single-Dose VialsAdrenalin® InjectionPositive
AI Analysis
Summary
DifGen Pharmaceuticals received FDA approval for Epinephrine Injection USP, 1 mg/mL, marking the company's second generic approval to Adrenalin® and expanding its injectable portfolio.
Outcome Details
FDA approval of Epinephrine Injection USP, 1 mg/mL as a generic to Adrenalin®
Importance:6/10
Sentiment:
0.75
FDA approvalgeneric druginjectableepinephrine
Read the original article
Published by PR Newswire Pharma on September 16, 2026 12:29 PM